FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

Haematologica. 2007 Aug;92(8):1127-30. doi: 10.3324/haematol.11288.

Abstract

We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / analysis
  • Antigens, CD / genetics*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Bone Marrow / chemistry
  • Bone Marrow / pathology
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Gene Rearrangement, B-Lymphocyte, Heavy Chain
  • Genotype
  • Humans
  • Immunoglobulin Heavy Chains / analysis
  • Immunotherapy*
  • Kaplan-Meier Estimate
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / genetics*
  • Lymphoma, Follicular / mortality
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Prednisone / administration & dosage
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • Receptors, IgG / analysis
  • Receptors, IgG / genetics*
  • Rituximab
  • Survival Analysis
  • Survival Rate
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Biomarkers, Tumor
  • FCGR3A protein, human
  • Fc gamma receptor IIA
  • Immunoglobulin Heavy Chains
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, IgG
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol